Symrise | Jotup

EQS-News: Symrise AG again raises sales significantly in 2023

Retrieved on:

星期三, 三月 13, 2024

The Symrise Group generated sales of € 4,730 million in the 2023 fiscal year, an increase of 2.4 % in the reporting currency.

Key Points:

The Symrise Group generated sales of € 4,730 million in the 2023 fiscal year, an increase of 2.4 % in the reporting currency.
Heinz-Jürgen Bertram, Chief Executive Officer of Symrise AG: “2023 was again a successful year of growth for Symrise.
Despite the good sales development in the 2023 fiscal year, earnings remained below expectations.
The cost of goods sold increased slightly faster than sales, which was mainly attributable to higher raw material and manufacturing costs.

Ceapro Inc. Reports 2023 Third Quarter and Nine-Month Financial Results and Operational Highlights

Retrieved on:

星期三, 十一月 29, 2023

EDMONTON, Alberta, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the third quarter and nine months ended September 30, 2023.

Key Points:

Further, over the past quarter we remained very active with strategic corporate initiatives aimed towards achieving a stated objective related to uplisting Ceapro to an international stock exchange.
Such formulations are to be resolubilized locally by Symrise and used for hair care and facial masks.
Financial Highlights for the Third Quarter and Nine-Month Period Ended September 30, 2023
Total sales of $2,619,000 for the third quarter of 2023 and $7,983,000 for the first nine months of 2023 compared to $3,845,000 and $15,517,000 for the comparative periods in 2022.
Cash flows used in operations of $2,017,000 for the first nine months in 2023 vs cash generated from operations of $5,644,000 in 2022.

EQS-News: Symrise AG: Symrise confirms profitable growth course

Retrieved on:

星期四, 十月 26, 2023

Symrise reaffirms long-term profitable corporate development; growth targets extended until 2028

Key Points:

Symrise reaffirms long-term profitable corporate development; growth targets extended until 2028
Symrise continued on its profitable growth course in the first nine months of the year and achieved organic sales growth of 7.4 %.
In light of the robust organic growth, Symrise has confirmed its growth and profitability targets, and at the same time extended its long-term growth objectives until 2028.
The Oral Care business unit achieved single-digit percentage organic growth with strong growth especially in the Asia/Pacific and Latin America regions.
Based on the positive business development in the first nine months, Symrise confirms its growth and profitability targets for the full year 2023.

BATH & BODY WORKS RALLIES CUSTOMERS TO SHARE WHAT MAKES THEM FEEL LUMINOUS

Retrieved on:

星期一, 十月 2, 2023

Cream, Body, Life, Atmosphere, Symrise, Perfume, Bath & Body Works, Bath, Eau, Lip Gloss, Empowerment, Iris, Luminous

COLUMBUS, Ohio, Oct. 2, 2023 /PRNewswire/ -- Radiant, rich and luxe are three words Bath & Body Works customers are using to describe its newest fragrance, Luminous, which officially launches in stores nationwide and online today. According to a Bath & Body Works survey, 77% of consumers love getting complimented on the scent they wear though 83% say they wear a fragrance for themselves rather than to impress others. So, for the launch of Luminous, the retailer is tapping into the power of fragrance and calling for customers to "share their shine" and show how this new fragrance makes them feel luminous from the inside out.

Key Points:

So, for the launch of Luminous, the retailer is tapping into the power of fragrance and calling for customers to "share their shine" and show how this new fragrance makes them feel luminous from the inside out.
With a purpose to make the world a brighter, happier place through the power of fragrance, Bath & Body Works is encouraging customers to let their radiance shine with its 'Share Your Shine' campaign.
By using #ShareYourShine and tagging @bathandbodyworks, customers can share how the fragrance makes them feel luminous.
As Bath & Body Works' largest holiday fragrance launch ever, Luminous is available in 30 products ranging from $1.95 to $59.95, making it an affordable luxury for many.

Ceapro Inc. Reports 2023 Second Quarter and Six-Month Financial Results and Provides Corporate Update

Retrieved on:

星期二, 八月 29, 2023

EDMONTON, Alberta, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the second quarter and six months ended June 30, 2023.

Key Points:

Further, over the past quarter we remained very active with our activities related to strategic corporate initiatives.
Stability studies are ongoing for the 30mg and 240mg pills formulation manufactured, packaged and labeled by Corealis Inc. GMP Manufacturing Services.
Studies showed statistically significant results characterizing the bioactivity of both Ceapro’s oat-derived bioactive products on wound healing and tissue regeneration.
Financial Highlights for the Second Quarter and the Six-Month Period Ended June 30, 2022
Sales of $1,869,000 for the second quarter of 2023 and $5,364,000 for the first six months of 2023 compared to $5,500,000 and $11,672,000 for the comparative periods in 2022.

Ceapro Extends Exclusive International Supply and Distribution Agreement with Leading Global Provider of Active Ingredients, Symrise

Retrieved on:

星期五, 八月 25, 2023

Organization, CZO, Pharmaceutical industry, Symrise

EDMONTON, Alberta, Aug. 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the signing of an amendment to its long-term agreement with German-based multinational, Symrise AG, for the distribution and commercialization of Ceapro’s high value active ingredients to major key international players in the cosmetic market. The three-year agreement, signed on January 1, 2022, will now extend until December 31, 2026.

Key Points:

The three-year agreement, signed on January 1, 2022, will now extend until December 31, 2026.
Under the agreement, Symrise is guaranteed to purchase minimum annual volumes of Ceapro’s high value active ingredients.
“We are very pleased to extend our supply and distribution agreement and reaffirm our strong relationship with longtime partner Symrise.
“Ceapro and Symrise have a long-standing relationship in product development that has benefitted both companies over the years,” added Timothy Kenny, Global President Cosmetic Ingredients, Symrise AG.

China Automotive Fragrance and Air Purification Systems Research Report 2023: Driving Wellness Innovations - Exploring the Integration of Fragrance and Air Purification - ResearchAndMarkets.com

Retrieved on:

星期五, 八月 18, 2023

The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points:

The "China Automotive Fragrance and Air Purification Systems Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
From 2020 to 2023, the installations of automotive air purification and fragrance systems will sustain steady growth.
It is predicted that in 2023 the installations of automotive air purification systems will exceed 6 million units, and that of fragrance systems will reach 1.03 million units.
1.2.2 Principle of Air Purification System: Sources of Pollution and Conventional Purification Process
1.2.4 Major Air Purification Technologies:

EQS-News: Symrise AG: Symrise continues growth course in the first half of 2023

Retrieved on:

星期三, 八月 2, 2023

Symrise continued its growth course in the first half of 2023 and achieved a sales increase of 6.8 % to € 2,414 million (H1 2022: € 2,260 million).

Key Points:

Symrise continued its growth course in the first half of 2023 and achieved a sales increase of 6.8 % to € 2,414 million (H1 2022: € 2,260 million).
Dr. Heinz-Jürgen Bertram, Chief Executive Officer of Symrise AG: “Symrise has a proven and stable business model with comparatively low risk content.
These measures reflect our ambition to enhance our competitiveness in a sustainable way.”
The Symrise Group achieved organic sales growth of 8.0 % in the first half of 2023.
Taste, Nutrition & Health achieved organic sales growth of 11.4 % in the first half of 2023.

SpendEdge Helped F&B Client Boost Profit Margin with Market Intelligence

Retrieved on:

星期三, 七月 26, 2023

F&B, Symrise, Maintenance, CIP, QC, Research, Life, Risk management, Givaudan

NEW YORK, July 26, 2023 /PRNewswire/ -- SpendEdge , a global leader in procurement market intelligence space recently engaged with an F&B client to explain the cost structure for synthetic strawberry flavoring.

Key Points:

NEW YORK, July 26, 2023 /PRNewswire/ -- SpendEdge , a global leader in procurement market intelligence space recently engaged with an F&B client to explain the cost structure for synthetic strawberry flavoring.
The client wanted to develop a cost model after analyzing the current manufacturing technologies/processes and capital investments.
It also wanted a cost components' list containing both direct and indirect cost categories.
Labor costs were calculated based on company-specific hourly internal billing rates of general chemists, flavor chemists, technicians, and QC analysts.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on:

星期四, 五月 25, 2023

EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points:

“Our team significantly advanced toward several key milestones related to new product development as well as strategic corporate initiatives.
Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
Announced positive results from animal studies conducted by Angiogenesis Foundation on a wound healing model.
Financial Highlights for the First Quarter Ended March 31, 2023
Total sales of $3,500,000 for the first quarter of 2023 compared to $6,172,000 for the comparative period in 2022.